The AD/PD 2025 Conference in Vienna brought together global leaders in neurodegenerative disease research, highlighting major strides in understanding and diagnosing Alzheimer’s and Parkinson’s disease. Quanterix was proud to be at the center of it all, with posters and presentations featuring our Simoa® technology.  

The Expanding Role of Fluid Biomarkers in Neurodegeneration 

The conference reinforced the critical role of fluid biomarkers in enhancing disease detection, tracking progression, and evaluating therapeutic impact. In Parkinson’s research, PET tracers and phosphorylated α-synuclein are emerging as promising tools, with potential for non-invasive, scalable diagnostics, areas where Quanterix excels. We also saw how Alzheimer’s research is transforming, with p-Tau217 playing a central role in improving trial enrollment and lowering barriers to participation.  

Simoa® Technology Powers Ultra-Sensitive Biomarker Detection 

Researchers repeatedly emphasized the power of highly sensitive immunoassays, like Simoa, to detect disease signals without the need for mass spectrometry. Sessions on extracellular vesicles revealed new avenues for precision diagnostics, and our tools helped researchers uncover disease-specific protein signatures previously undetectable. Findings around sex-specific mechanisms and inflammatory pathways in Alzheimer’s further showed how ultra-sensitive detection is essential for personalized care.  

Driving Innovation with Plasma Biomarkers and Inclusive Research 

Exciting studies demonstrated how plasma-based biomarkers such as SNAP25, NfL, GFAP, and p-tau can be reliably measured, thanks in large part to Quanterix technology. Data from diverse populations, including Hispanic/Latino cohorts, underscored the need for inclusive biomarker validation, a mission we support with great urgency. From preclinical detection to population-wide studies, Simoa enabled researchers to draw sharper connections between biology and disease. 

The Future of Disease Detection: Dried Blood Spot Kits and Epigenetic Clocks 

Our recently launched dried blood spot kit featured in presentations exploring Alzheimer’s detection in capillary blood, is a game-changer for accessibility. New evidence also highlighted the potential of combining epigenetic clocks with plasma biomarkers for more precise risk prediction. Across the board, fluid biomarkers emerged as more dynamic indicators of disease biology than imaging alone.  

Quanterix: Empowering the Future of Neurological Research 

Quanterix is proud to empower the scientific community with the tools needed to move from discovery to impact. We left Vienna inspired and energized to continue enabling breakthroughs that will define the future of neurology. 

Explore Blood-Based Biomarkers of Brain Health 

The advancements discussed at AD/PD 2025 reflect what’s possible with ultra-sensitive tools like Simoa®. With up to 1000x greater sensitivity than traditional immunoassays, Simoa® detects CNS biomarkers in blood that were previously limited to CSF.  

Explore our full neurology assay menu—including NfL, GFAP, p-Tau variants, BD-Tau, SNAP-25, and more—powering research across major neurological disorders in this Brain Health Brochure.